Introduction
============

Since the advent of combination antiretroviral therapy (ART), the survival and quality of life of people living with HIV (PLWH) have steadily improved, thereby increasing the number of older PLWH.[@b1-tcrm-14-2229],[@b2-tcrm-14-2229] A 2013 estimate revealed that \~4.2 million PLWH across the world were \>50 years old, and it is expected that this number will continue to increase.[@b3-tcrm-14-2229] An aging population of PLWH is likely to experience age-associated illnesses such as cardiovascular diseases (CVD), cancers, osteoporosis, and cognitive impairment, similar to the general population. These age-related comorbidities may require chronic treatment. Consequently, it is necessary to not only suppress the viral load of HIV but also control age-related, non-AIDS-related illnesses for effectively managing an aging population of PLWH.

The combination of antiretroviral (ARV) and non-ARV medications in an aging population of PLWH may lead to adverse events (AEs), drug--drug interactions (DDIs), and poor drug adherence, all of which have negative effects on the efficacy and safety of ARV and non-ARV medications.[@b4-tcrm-14-2229]--[@b8-tcrm-14-2229] In particular, the rate of incidence of DDIs is likely to rise in an aging population of PLWH due to polypharmacy for the treatment of multiple comorbidities along with the HIV infection.[@b4-tcrm-14-2229],[@b9-tcrm-14-2229]--[@b11-tcrm-14-2229] According to a retrospective clinical study involving HIV-positive patients aged ≥50 years, the average number of total prescribed medications was 14.2±5.9, and that of concomitant medications excluding ARVs was 11.6±5.7.[@b7-tcrm-14-2229] Twenty-five contraindicated DDIs were found to occur in 20 (8.1%) HIV-infected patients.[@b7-tcrm-14-2229] In other retrospective clinical studies, potential and contraindicated DDIs were found in 71 (62.8%) and 6 (5.3%) patients, respectively, out of 113 HIV-positive patients receiving comedications.[@b9-tcrm-14-2229]

The incidence rate of DDIs in HIV-positive patients may vary according to the ART regimens used. Potential DDIs may occur more frequently in HIV-positive patients on ritonavir (RTV)- or cobicistat (COBI)-boosted protease inhibitor (PI)-based or on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART regimens.[@b11-tcrm-14-2229],[@b12-tcrm-14-2229] PI-based ART regimens are nine times as likely to induce potential DDIs as regimens without PIs.[@b13-tcrm-14-2229] Additionally, patients treated with ART regimens containing NNRTIs were likely to experience about 4.3 times as many potential DDIs as their counterparts.[@b13-tcrm-14-2229] Therefore, it is important that appropriate ART regimens that are less likely to interact with other comedications and less likely to affect non-AIDS illnesses are used, especially in older HIV-positive patients who are already suffering from comorbidities.

This study was aimed to investigate ARV usage patterns among HIV-positive patients in an age-wise manner and to evaluate the potential or contraindicated DDIs between ARVs and concomitantly prescribed drugs.

Methods
=======

The Institutional Review Board (IRB) of Chonbuk National University Hospital granted ethical approval for this study (CUH 2017-11-028). The IRB waived the requirement for obtaining informed consent from the participants in this study since their data were deidentified and anonymously encoded prior to commencing analyses. This study was retrospectively conducted with the following categories of patients visiting Chonbuk National University Hospital, located in the city of Jeonju in North Jeolla Province of South Korea, between October 2011 and September 2017. The inclusion criteria were the following: 1) age ≥18 years; 2) diagnosis of HIV infection; and 3) having received ART at least once.

A retrospective chart review of the electronic medical records of selected HIV-infected patients was conducted, in which a trained hospital pharmacist collected the following information from paper case report forms: demographic characteristics (sex, age, weight, height, and body mass index), risk factors for HIV infection, prior HIV treatment, hepatitis B virus and hepatitis C virus positivity, comorbidities, prescribed medications for HIV infection and other diseases, and laboratory values (HIV-1 RNA copy, CD4+T-cell count, and estimated glomerular filtration rate \[eGFR\]).

Older adults living with HIV infection may suffer from more comorbidities and experience more rapid physical and cognitive aging than their normal counterparts do. Study of HIV-related literature reveals that the aging HIV-infected population is represented by patients aged ≥50 years.[@b14-tcrm-14-2229] To compare the differences in the use of ARV drug regimens among individuals of different ages, the selected patients were divided into two groups, namely, patients \<50 years and patients ≥50 years. In order to assess the usage patterns of HIV regimens in a year-wise manner during the study period, the regimens were categorized on the basis of the combination of two nucleoside reverse transcriptase inhibitors (NRTIs) and a third ARV agent based on recently published HIV treatment guidelines.[@b15-tcrm-14-2229],[@b16-tcrm-14-2229] The potential and contraindicated DDIs between ARV agents and concomitantly prescribed drugs during the study period were also investigated using the Liverpool HIV Drug Interactions website.[@b17-tcrm-14-2229]

All the analyses were conducted using SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA). The mean and SD were used for continuous variables, whereas the frequencies (n) and percentages (%) were used for the categorical variables. The independent *t*-test was performed for comparing the differences in the means of the continuous variables, and the chi-squared test or Fisher's exact test was also conducted for comparing the differences in the proportions of the categorical variables. *P*-values \<0.05 were considered to be statistically significant.

Results
=======

During the study period, 207 patients were diagnosed with HIV infection, of which 183 patients (104 patients aged \<50 years and 79 patients aged ≥50 years) who met the aforementioned inclusion criteria were selected for the analysis ([Figure 1](#f1-tcrm-14-2229){ref-type="fig"}). The baseline characteristics of the patients are presented in [Table 1](#t1-tcrm-14-2229){ref-type="table"} and arranged according to their ages. The average age of all the patients was 47.3±12.4 years, and most of the patients (86.9%) were males. The eGFR levels of the patients aged \<50 years were significantly higher than those of the patients aged ≥50 years. However, the incidence rates of diabetes mellitus (DM), hypertension (HTN), cancer, and benign prostatic hyperplasia were significantly higher in the patients aged ≥50 years than in patients aged \<50 years.

The ARV drug combination regimens used during the study period are presented in a year-wise manner in [Table 2](#t2-tcrm-14-2229){ref-type="table"}. In 2011, the combination of NRTIs and PIs was most frequently prescribed in both groups of patients. Between 2011 and 2014, the prescription rate of this combination remained almost stable; however, the prescription rate gradually declined after 2014. The prescription rate of the combination of NRTIs and integrase strand transfer inhibitors (INSTIs) had tended to gradually increase ever since its first use in 2012, and this combination was the most frequently prescribed ARV drug regimen in 2017.

The prescribed ARV drugs are presented in a year-wise manner in [Table 3](#t3-tcrm-14-2229){ref-type="table"}. Although zidovudine (ZDV)/lamivudine (3TC) was most frequently prescribed in 2011 (54.7%), its prescription rate gradually decreased by 2.5% in 2017. The prescription rate of abacavir (ABC)/3TC remained stable throughout the study period. The prescription rate of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) exhibited a steady increase from 2012 (31.0%) to 2016 (60.4%). However, in 2017, this rate became almost half (28.1%) of that in 2016. The prescription rate of tenofovir alafenamide (TAF)/FTC, which was first used in 2017, was 31.3%, which may account for the decrease in the prescription rate of TDF/FTC. Rilpivirine (RPV) had been the most frequently prescribed NNRTI ever since its first use in 2015. Although efavirenz had been the most frequently prescribed NNRTI from 2011 to 2015, its prescription ended in 2017. Atazanavir and lopinavir (LPV)/RTV had been steadily prescribed until the introduction of elvitegravir (EVG) combined with COBI in 2015. In 2017, the prescription rate of boosted PIs with RTV or COBI was 97.8%. The prescription rates of dolutegravir (DTG) and EVG/COBI have been gradually increasing since their first use in 2015, whereas that of raltegravir (RAL) decreased after 2014.

The classes of drugs coadministered with ARVs are presented in an age-wise manner in [Table 4](#t4-tcrm-14-2229){ref-type="table"}. The drug classes that had significantly higher rates of use in patients aged ≥50 years than in those aged \<50 years were drugs prescribed for ailments of the alimentary tract and metabolism; dermatologicals; and drugs for diseases of the cardiovascular system, blood and blood forming organs, and the genitourinary system and sex hormones.

Based on the data obtained by using the Liverpool HIV Drug Interactions website, the potential or contraindicated DDIs are summarized in [Table 5](#t5-tcrm-14-2229){ref-type="table"}. A total of 194 potential or contraindicated DDIs were identified, and among them, 12 (6.2%) contraindicated DDIs were found. Contraindicated DDIs occurred most frequently between boosted PIs with RTV or EVG/COBI and coprescribed drugs such as alfuzosin, clopidogrel, quetiapine, rifampicin, simvastatin, and phenytoin.

Discussion
==========

In this study, the usage patterns of ARV regimens in HIV-positive patients were studied in an age-wise manner and potential or contraindicated DDIs between ARV and non-ARV drugs were investigated. Recently, the most frequently prescribed regimen involved treatment with NRTIs/INSTIs followed by therapy with NRTIs/PIs. ABC/3TC, TDF/FTC, and TAF/FTC among the NRTIs, LPV/RTV among the PIs, and EVG/COBI and DTG among the INSTIs were frequently prescribed. In addition, DDIs between boosted PIs with RTV or EVG/COBI and coprescribed drugs occurred most frequently.

Numerous diseases such as osteoporosis, DM, chronic liver disease, chronic kidney disease, and CVDs have higher rates of occurrence in the aging population of PLWH than in their HIV-uninfected counterparts.[@b18-tcrm-14-2229]--[@b20-tcrm-14-2229] Therefore, in order to effectively manage health conditions in the aging population of PLWH, it is not only essential to suppress the viral load of HIV and allow the immune system to recover but also to control age-associated, non-AIDS illnesses. However, the combined use of ARV and non-ARV drugs is likely to cause various drug-related problems such as DDIs.

The coformulation of ZDV and 3TC was a preferred choice for the treatment of HIV infections in 2011, but it was rarely used in 2017. Instead of this NRTI combination, tenofovir-based combinations (TDF/FTC and TAF/FTC) or the ABC/3TC combination was usually administered. This trend may be due to several reasons as stated hereafter. The prolonged use of ZDV can lead to more severe adverse reactions such as hematological toxicities (anemia and/or neutropenia) and symptomatic myopathy.[@b21-tcrm-14-2229] ZDV/3TC requires twice-daily dosing for effectively suppressing the levels of HIV RNA, whereas the TDF/FTC, TAF/FTC, and ABC/3TC combinations require once-daily dosing, which may reduce the pill burden for HIV-infected patients and improve their medication adherence rates.[@b21-tcrm-14-2229]--[@b26-tcrm-14-2229] Furthermore, it was reported that the efficacy of the ZDV/3TC combination was less robust than TDF/FTC-based ART in achieving viral suppression.[@b27-tcrm-14-2229],[@b28-tcrm-14-2229]

The most frequently prescribed regimen in 2017 was NRTIs/INSTIs followed by NRTIs/PIs. Specifically, TDF/FTC/COBI/EVG (Stribild^®^) and TAF/FTC/COBI/EVG (Genvoya^®^), approved by the US Food and Drug Administration (FDA) in 2012 and 2015, respectively, consisted of two NRTIs and one INSTI with one booster.[@b24-tcrm-14-2229],[@b25-tcrm-14-2229] The ABC/3TC/DTG (Triumeq^®^) combination, consisting of two NRTIs and one INSTI, was approved by the FDA in 2014.[@b26-tcrm-14-2229] This tendency might have appeared owing to the use of the once-daily, single-tablet regimens as the initial therapy for treatment-naïve patients and switching to simplified, less toxic regimens for treatment-experienced patients.[@b29-tcrm-14-2229],[@b30-tcrm-14-2229]

Until 2016, Stribild had been the only tenofovir-based combination; however, in 2017, Genvoya was introduced in the hospital where this study was conducted. As shown in [Table 3](#t3-tcrm-14-2229){ref-type="table"}, the prescription rate of TDF/FTC, the two NRTIs in Stribild, in 2017 (28.1%) was almost half of that in 2016 (60.4%). However, the prescription rate of TAF/FTC, the two NRTIs in Genvoya, was 31.3% in 2017, which is likely to account for the decrease in the prescription rate of TDF/FTC in 2017. This result may be further explained by the differences in the efficacy and safety of the regimens containing TDF/FTC and TAF/FTC for the management of HIV infection. In comparison to TDF/FTC-based regimens, TAF/FTC-based regimens have similar or better efficacy, and their use improved renal and bone health.[@b31-tcrm-14-2229]--[@b33-tcrm-14-2229] According to the study by Sax et al, which employed treatment-naïve HIV-1-infected patients, high virological success rates (HIV-1 RNA \<50 copies/mL) were achieved at week 48 in patients receiving both TAF/FTC/COBI/EVG (92%) and TDF/FTC/COBI/EVG (90%).[@b34-tcrm-14-2229] In the study by Mills et al on virologically suppressed HIV-1-infected patients, virological success (HIV-1 RNA \<50 copies/mL) at week 48 occurred in 97% of the patients receiving TAF/FTC/COBI/EVG and 93% of those administered with the TDF-containing regimen (*P*\<0.0002).[@b35-tcrm-14-2229] In particular, TAF/FTC/COBI/EVG was preferred over TDF/FTC/COBI/EVG for HIV-1-infected patients who were aged ≥50 years.[@b33-tcrm-14-2229],[@b34-tcrm-14-2229]

The intracellular concentration of tenofovir-diphosphate, which is an active metabolite, was approximately four times higher after treatment with TAF than that after treatment with TDF.[@b34-tcrm-14-2229] This indicated that compared with TDF, TAF is required at much lower doses, and the systemic exposure of tenofovir was also expected to be much lower in patients under therapy with TAF than in those treated with TDF.[@b34-tcrm-14-2229] Consequently, this is likely to improve tenofovir-associated AEs such as renal toxicity and reduced bone mineral density (BMD). Sax et al reported that therapy with TAF/FTC/COBI/EVG induced a significantly smaller increase in mean serum creatinine (0.08 vs 0.12 mg/dL; *P*\<0.0001), significantly lesser proteinuria (median % change, −3 vs 20; *P*\<0.0001), and a significantly smaller decrease in the BMD of the spine (mean % change, −1.30 vs −2.86; *P*\<0.0001) and hip (−0.66 vs −2.95; *P*\<0.0001) at week 48 than those observed after treatment with TDF/FTC/COBI/EVG.[@b34-tcrm-14-2229] Mills et al additionally reported that compared with treatment with TDF-containing regimens, therapy with TAF/FTC/COBI/EVG significantly improved the BMD of the spine (mean % change from the baseline, 1.56 vs −0.44; *P*\<0.0001) and hip (1.47 vs −0.34; *P*\<0.0001) and the mean serum creatinine (−0.4 vs 2.9 μmol/L; *P*\<0.0001) at week 48.[@b35-tcrm-14-2229] Comprehensively, TAF/FTC/COBI/EVG may be a better choice than TDF/FTC/COBI/EVG for the treatment of HIV-infected patients, especially those aged ≥50 years, and patients who have reduced renal function, medical history of fractures, osteopenia, or osteoporosis.

Exposure to ABC, the NRTI present in Triumeq, may lead to an increase in the risks of CVD events, such as coronary artery disease and myocardial infarction.[@b31-tcrm-14-2229],[@b36-tcrm-14-2229] According to the study that assessed the risk of CVD events in HIV-infected patients administered with ARV drugs, a higher incidence rate of CVD events was observed in the patients who were currently exposed to ABC than in those who were currently exposed to other ARV drugs (9.74/1,000 person-years vs 5.75/1,000 person-years).[@b36-tcrm-14-2229] The HRs of CVD events for patients under current (1.43; *P*=0.001), recent (1.41; *P*=0.001), and cumulative (1.18 \[per year\]; *P*=0.002) exposure to ABC increased with statistical significance.[@b36-tcrm-14-2229] The HR of CVD events for cumulative exposure to ABC also increased for up to 24 months and decreased thereafter.[@b36-tcrm-14-2229] Consequently, ABC should be cautiously used in HIV-infected patients, especially those aged ≥50 years, and patients with risk factors (such as HTN, hyperlipidemia, DM, and smoking) for coronary artery disease and myocardial infarction, by appropriately managing those risk factors prior to initiating regimens containing ABC.

The DDIs between ART and non-ART drugs make it difficult to design effective and safe ART regimens, especially in older HIV-infected patients (≥50 years of age), who are more likely to take one or more comedications with ART drugs in order to manage multiple comorbidities than younger HIV-infected patients (\<50 years of age) are.[@b4-tcrm-14-2229],[@b37-tcrm-14-2229] The independently associated variables with potential or contraindicated DDIs include older age, dyslipidemia, higher daily drug burden of non-ARTs, and prescription of PIs.[@b4-tcrm-14-2229] In this study, contraindicated drugs, such as alfuzosin, clopidogrel, quetiapine, rifampicin, simvastatin, and pheny-toin, were frequently prescribed along with ARV regimens including pharmacokinetic boosters (ie, RTV and COBI). Potential DDIs mainly occurred between boosted ARV regimens and non-ART drugs, such as drugs prescribed for gastrointestinal, metabolic, cardiovascular, and central nervous system ailments, which was similar to the results obtained from previous studies.[@b4-tcrm-14-2229],[@b37-tcrm-14-2229] ARV regimens including pharmacokinetic boosters should be cautiously administered to poly-medicated patients. Other regimens including INSTIs (ie, DTG and RAL) are preferable in those cases. Additionally, comprehensive pharmacist-led medication review and intervention in HIV-positive patients, especially those under complex medication regimens, may reduce the incidence rates of AEs and DDIs, as demonstrated in a previous study.[@b7-tcrm-14-2229]

This study has some limitations which should be borne in mind while interpreting the results. All data pertaining to the prescribed medications including ART agents were retrospectively collected by reviewing the electronic medical charts of the patients. Therefore, it could not be confirmed whether the patients had actually partaken of the prescribed medication and whether the DDIs had actually occurred. This limitation may be solved by providing the patients with self-reporting questionnaires concerning medication adherence and DDIs in the future. It was difficult to determine when the comorbidities had occurred owing to the cross-sectional design of this study. The last limitation was the representativeness of the patients included in this study. Most of the patients were likely to be current residents of North Jeolla Province in South Korea; thus, it may be somewhat difficult to generalize the results of this study and extend them to the residents of other regions of South Korea. In order to overcome this shortcoming, it is necessary to collaborate with other hospitals in the near future. However, since studies on the age-wise usage pattern of ARVs and their DDIs with non-ARV drugs have been rarely conducted in Korea, this study is of significance and could aid the identification of more appropriate ARV drug regimens having few DDIs with non-ARVs in an aging population of PLWH in Korea.

Conclusion
==========

The advent of combination ARTs has enabled PLWH to live up to older ages, causing these individuals to experience age-related illnesses, which necessitates the use of non-ARV medications for managing these illnesses. It is important to use appropriate ART regimens that are less likely to interact with other comedications and affect non-AIDS illnesses. The most frequently prescribed ART regimen involves treatment with NRTIs/INSTIs (ie, ABC/3TC/DTG, TAF/FTC/COBI/EVG, and TDF/FTC/COBI/EVG). TAF/FTC/COBI/EVG may be a better option than TDF/FTC/COBI/EVG and ABC/3TC/DTG for patients, especially those aged ≥50 years, and those having low BMD, reduced kidney function, or cardiovascular diseases. EVG/COBI and boosted PIs with RTV or COBI may not be good options for poly-medicated patients due to the high risks of DDIs, and DTG or RAL regimens may be preferred in this situation. However, EVG/COBI was most frequently prescribed in 2017. Further research should be performed to evaluate the impact of pharmacist-led medication review and intervention on AEs and DDIs in HIV-positive patients in Korea under complex medication regimens.
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###### 

Baseline characteristics of the patients included in the study

  Variable                                      All patients (n=183)   \<50 years (n=104)    ≥50 years (n=79)    *P*-value
  --------------------------------------------- ---------------------- --------------------- ------------------- -----------
                                                                                                                 
  Age, mean (SD), years                         47.3 (12.4)            38.7 (7.8)            58.5 (7.2)          \<0.001
  Sex, n (%)                                                                                                     
   Male                                         159 (86.9)             89 (85.6)             70 (88.6)           0.547
   Female                                       24 (13.1)              15 (14.4)             9 (11.4)            
  BMI, mean (SD), kg/m^2^                       22.3 (3.4)             21.7 (3.5)            23.1 (3.2)          0.056
  Risk factors for HIV infection, n (%)                                                                          
   Intravenous drug use                         1 (0.5)                1 (1.0)               0 (0.0)             
   Hetero/homosexual                            37 (20.2)              19 (18.3)             18 (22.8)           0.522
   Unknown                                      145 (79.2)             84 (80.8)             61 (77.2)           
  Previous HIV treatment, n (%)                                                                                  
   Naïve                                        108 (59.0)             66 (63.5)             42 (53.2)           0.161
   Experienced                                  75 (41.0)              38 (36.5)             37 (46.8)           
  HIV-1 RNA copy, mean (SD), copies/mL          195,249 (93,942.4)     292,763 (122,477.8)   62,630 (14,359.5)   0.107
  HIV-1 RNA copy, n (%)                                                                                          
   HIV-1 RNA copy\<100,000 copies/mL            136 (76.8)             72 (70.6)             64 (85.3)           
   HIV-1 RNA copy≥100,000 copies/m              41 (23.2)              30 (29.4)             11 (14.7)           0.026
  CD4+T-cell count, mean (SD), cells/mm^3^      316.3 (223.3)          296.9 (220.6)         343.2 (225.6)       0.175
  CD4+T-cell count, cells/mm^3^, n (%)                                                                           
   \<50                                         27 (15.3)              18 (17.6)             9 (12.2)            
   ≥50 to \<200                                 33 (18.8)              19 (18.6)             14 (18.9)           0.601
   ≥200                                         116 (65.9)             65 (63.7)             51 (68.9)           
  HBV positive, n (%)                           11 (6.0)               4 (3.7)               7 (8.9)             0.212
  HCV positive, n (%)                           1 (0.5)                1 (1.0)               0 (0.0)             1.000
  eGFR, mean (SD), mL/min/1.73 m^2^             108.0 (20.2)           113.0 (21.2)          100.5 (16.2)        0.004
  Comorbidity, n (%)                                                                                             
   Diabetes mellitus                            28 (15.3)              6 (5.8)               22 (27.8)           \<0.001
   Hypertension                                 10 (5.5)               1 (1.0)               9 (11.4)            0.003
   Dyslipidemia                                 4 (2.2)                1 (1.0)               3 (3.8)             0.317
   Cancer                                       15 (8.2)               4 (3.8)               11 (13.9)           0.014
   Asthma                                       3 (1.6)                1 (1.0)               2 (2.5)             0.579
   Chronic obstructive pulmonary disease        1 (0.5)                0 (0.0)               1 (1.3)             0.432
   Dementia, cognitive impairment               5 (2.7)                2 (1.9)               3 (3.8)             0.653
   Chronic kidney disease                       4 (2.2)                3 (2.9)               1 (1.3)             0.635
   Benign prostatic hyperplasia                 9 (4.9)                0 (0.0)               9 (11.4)            \<0.001
   Erectile dysfunction                         4 (2.2)                2 (1.9)               2 (2.5)             1.000
   Myelodysplastic syndromes                    1 (0.5)                0 (0.0)               1 (1.3)             0.432
   Gastritis, gastroesophageal reflux disease   17 (9.3)               7 (6.7)               10 (12.7)           0.171
   Thyroid disease                              1 (0.5)                0 (0.0)               1 (1.3)             0.432
   Seizure                                      4 (2.2)                4 (3.8)               0 (0.0)             0.135
   Stroke                                       7 (3.8)                2 (1.9)               5 (6.3)             0.242
   Acute coronary syndrome                      2 (1.1)                1 (1.0)               1 (1.3)             1.000
   Depression                                   8 (4.4)                4 (3.8)               4 (5.1)             1.000
  Opportunistic infections, n (%)                                                                                
   Syphilis                                     29 (15.8)              15 (14.4)             14 (17.7)           0.545
   Pneumocystis pneumonia                       23 (12.6)              14 (13.5)             9 (11.4)            0.676
   Candidiasis                                  22 (12.0)              15 (14.4)             7 (8.9)             0.252
   Varicella-Zoster virus                       14 (7.7)               9 (8.7)               5 (6.3)             0.558
   Tuberculosis                                 9 (4.9)                5 (4.8)               4 (5.1)             0.937
   Cytomegalovirus                              9 (4.9)                6 (5.8)               3 (3.8)             0.541
   Human papillomavirus                         9 (4.9)                5 (4.8)               4 (5.1)             0.937
   Pneumonia                                    9 (4.9)                4 (3.8)               5 (6.3)             0.442
   Herpes simplex virus                         8 (4.4)                6 (5.8)               2 (2.5)             0.289
   *Mycobacterium avium* complex                4 (2.2)                3 (2.9)               1 (1.3)             0.458
   Cryptococcosis                               4 (2.2)                2 (1.9)               2 (2.5)             0.780
   JC virus                                     2 (1.1)                2 (1.9)               0 (0.0)             0.218
   Toxoplasmic encephalitis                     2 (1.1)                0 (0.0)               2 (2.5)             0.103
   Kaposi's sarcoma                             1 (0.5)                1 (1.0)               0 (0.0)             0.382
  ARV regimens, n (%)                                                                                            
   NRTIs/NNRTIs                                 37 (20.2)              21 (20.2)             16 (20.3)           
   NRTIs/PIs                                    100 (54.6)             60 (57.7)             40 (50.6)           0.649
   NRTIs/INSTIs                                 43 (23.5)              21 (20.2)             22 (27.8)           
   NRTIs/NNRTIs/PIs                             3 (1.6)                2 (1.9)               1 (1.3)             

**Abbreviations:** ARV, antiretroviral; BMI, body mass index; eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; INSTIs, integrase strand transfer inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors.

###### 

Antiretroviral drug combination regimens used during the study period

  Regimen               Age, years   Year, n (%)                                                               
  --------------------- ------------ ------------- ----------- ----------- ----------- ----------- ----------- ------------
                                                                                                               
  NRTIs/NNRTIs          Total        9 (17.0)      11 (15.5)   8 (9.0)     13 (11.3)   11 (8.5)    23 (14.9)   8 (5.0)
  \<50                  5 (9.4)      6 (8.5)       3 (3.4)     5 (4.3)     4 (3.1)     11 (7.1)    3 (1.9)     
  ≥50                   4 (7.5)      5 (7.0)       5 (5.6)     8 (7.0)     7 (5.4)     12 (7.8)    5 (3.1)     
                                                                                                               
  NRTIs/PIs             Total        40 (75.5)     50 (70.4)   61 (68.5)   76 (66.1)   67 (51.5)   64 (41.6)   38 (23.8)
  \<50                  23 (43.4)    30 (42.3)     36 (40.5)   45 (39.1)   39 (30.0)   40 (26.0)   24 (15.0)   
  ≥50                   17 (32.1)    20 (28.2)     25 (28.1)   31 (27.0)   28 (21.5)   24 (15.6)   14 (8.8)    
                                                                                                               
  NRTIs/INSTIs          Total        --            7 (9.9)     17 (19.1)   23 (20.0)   45 (34.6)   59 (38.3)   106 (66.3)
  \<50                  --           --            5 (5.6)     7 (6.1)     20 (15.4)   30 (19.5)   58 (36.3)   
  ≥50                   --           7 (9.9)       12 (13.5)   16 (13.9)   25 (19.2)   29 (18.8)   48 (30.0)   
                                                                                                               
  NRTIs/NNRTIs/PIs      Total        3 (5.7)       --          --          --          --          --          --
  \<50                  2 (3.8)      --            --          --          --          --          --          
  ≥50                   1 (1.9)      --            --          --          --          --          --          
                                                                                                               
  NRTIs/PIs/INSTIs      Total        --            --          1 (1.1)     1 (0.9)     2 (1.5)     2 (1.3)     1 (0.6)
  \<50                  --           --            --          --          1 (0.8)     1 (0.6)     --          
  ≥50                   --           --            1 (1.1)     1 (0.9)     1 (0.8)     1 (0.6)     1 (0.6)     
                                                                                                               
  NRTIs/NNRTIs/INSTIs   Total        --            --          --          --          --          --          1 (0.6)
  \<50                  --           --            --          --          --          --          --          
  ≥50                   --           --            --          --          --          --          1 (0.6)     
                                                                                                               
  Non-NRTIs             Total        1 (1.9)       3 (4.2)     2 (2.2)     2 (1.7)     5 (3.8)     6 (3.9)     6 (3.8)
  \<50                  1 (1.9)      2 (2.8)       2 (2.2)     2 (1.7)     3 (2.3)     3 (1.9)     3 (1.9)     
  ≥50                   --           1 (1.4)       --          --          2 (1.5)     3 (1.9)     3 (1.9)     

**Abbreviations:** INSTIs, integrase strand transfer inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors.

###### 

NRTIs, NNRTIs, PIs, and INSTIs used during the study period

  Antiretroviral drug   Age, years                                                                                                         
  --------------------- ------------ ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- -----------------
                                                                                                                                           
  ABC/3TC               Total        12 (22.6)        18 (25.4)        28 (31.5)        40 (34.8)        42 (32.3)        50 (32.5)        55 (34.4)
  \<50                  8 (15.1)     11 (15.5)        16 (18.0)        22 (19.1)        22 (16.9)        28 (18.2)        33 (20.6)        
  ≥50                   4 (7.5)      7 (9.9)          12 (13.5)        18 (15.7)        20 (15.4)        22 (14.3)        22 (13.8)        
                                                                                                                                           
  TDF/FTC               Total        --               22 (31.0)        32 (36.0)        46 (40.0)        77 (59.2)        93 (60.4)        45 (28.1)
  \<50                  --           10 (14.1)        16 (18.0)        24 (20.9)        39 (30.0)        52 (33.8)        27 (16.9)        
  ≥50                   --           12 (16.9)        16 (18.0)        22 (19.1)        38 (29.2)        41 (26.6)        18 (11.3)        
                                                                                                                                           
  ZDV/3TC               Total        29 (54.7)        28 (39.4)        27 (31.5)        27 (23.5)        7 (5.4)          5 (3.2)          4 (2.5)
  \<50                  17 (32.1)    15 (21.1)        12 (13.5)        11 (9.6)         4 (3.1)          2 (1.3)          1 (0.6)          
  ≥50                   12 (22.6)    13 (18.3)        15 (18.0)        16 (13.9)        3 (2.3)          3 (1.9)          3 (1.9)          
                                                                                                                                           
  3TC/d4T               Total        7 (13.2)         --               --               --               --               --               --
  \<50                  2 (3.8)      --               --               --               --               --               --               
  ≥50                   5 (9.4)      --               --               --               --               --               --               
                                                                                                                                           
  TAF/FTC               Total        --               --               --               --               --               --               50 (31.3)
  \<50                  --           --               --               --               --               --               26 (16.3)        
  ≥50                   --           --               --               --               --               --               24 (15.0)        
                                                                                                                                           
  3TC/ddI               Total        1 (1.9)          --               --               --               --               --               --
  \<50                  1 (1.9)      --               --               --               --               --               --               
  ≥50                   --           --               --               --               --               --               --               
                                                                                                                                           
  3TC                   Total        3 (5.7)          --               --                                                 --               --
  \<50                  2 (3.8)      --               --                                                 --               --               
  ≥50                   1 (1.9)      --               --               --               --               --               --               
                                                                                                                                           
  Not used              Total        1 (1.9)          3 (4.2)          2 (2.2)          2 (1.7)          4 (3.1)          6 (3.9)          6 (3.8)
  \<50                  1 (1.9)      2 (2.8)          2 (2.2)          2 (1.7)          2 (1.5)          3 (1.9)          3 (1.9)          
  ≥50                   --           1 (1.4)          --               --               2 (1.5)          3 (1.9)          3 (1.9)          
                                                                                                                                           
  **NNRTIs**                         **(n**=**13)**   **(n**=**14)**   **(n**=**10)**   **(n**=**15)**   **(n**=**15)**   **(n**=**28)**   **(n**=**14)**
                                                                                                                                           
  EFV                   Total        9 (69.2)         11 (78.6)        8 (88.9)         13 (86.7)        10 (66.7)        2 (7.1)          --
  \<50                  5 (38.5)     6 (42.9)         3 (30.0)         5 (33.3)         4 (26.7)         1 (3.6)          --               
  ≥50                   4 (30.8)     5 (35.7)         5 (50.0)         8 (53.3)         6 (40.0)         1 (3.6)          --               
                                                                                                                                           
  ETR                   Total        1 (7.7)          3 (21.4)         2 (20.0)         2 (13.3)         4 (26.7)         6 (21.4)         6 (42.9)
  \<50                  1 (7.7)      2 (14.3)         --               --               3 (20.0)         3 (10.7)         3 (21.4)         
  ≥50                   --           1 (7.1)          --               --               1 (6.7)          3 (10.7)         3 (21.4)         
                                                                                                                                           
  NVP                   Total        3 (23.1)         --               --               --               --               --               --
  \<50                  2 (15.4)     --               --               --               --               --               --               
  ≥50                   1 (7.7)      --               --               --               --               --               --               
                                                                                                                                           
  RPV                   Total        --               --               --               --               1 (6.7)          20 (71.4)        8 (57.1)
  \<50                  --           --               --               --               --               10 (35.7)        4 (28.6)         
  ≥50                   --           --               --               --               1 (6.7)          10 (35.7)        4 (28.6)         
                                                                                                                                           
  **PIs**                            **(n**=**44)**   **(n**=**53)**   **(n**=**64)**   **(n**=**79)**   **(n**=**74)**   **(n**=**72)**   **(n**=**45)**
                                                                                                                                           
  ATV                   Total        13 (29.5)        17 (32.1)        19 (29.7)        17 (21.5)        6 (8.1)          3 (4.2)          1 (2.2)
  \<50                  5 (11.4)     9 (17.0)         10 (15.6)        9 (11.4)         3 (4.1)          1 (1.4)          1 (2.2)          
  ≥50                   8 (18.2)     8 (15.1)         9 (14.1)         8 (10.1)         3 (4.1)          2 (2.8)          --               
                                                                                                                                           
  ATV/RTV               Total        --               --               --               7 (8.9)          6 (8.1)          4 (5.6)          1 (2.2)
  \<50                  --           --               --               4 (5.1)          5 (6.8)          4 (5.6)          1 (2.2)          
  ≥50                   --           --               --               3 (3.8)          1 (1.4)          --               --               
                                                                                                                                           
  ATV/COBI              Total        --               --               --               --               --               --               2 (4.4)
  \<50                  --           --               --               --               --               --               1 (2.2)          
  ≥50                   --           --               --               --               --               --               1 (2.2)          
                                                                                                                                           
  LPV/RTV               Total        27 (61.4)        30 (56.6)        39 (60.9)        45 (57.0)        35 (47.3)        33 (45.8)        30 (66.7)
  \<50                  18 (40.9)    19 (35.8)        24 (37.5)        27 (34.2)        19 (25.7)        19 (26.4)        17 (37.8)        
  ≥50                   9 (20.5)     11 (20.8)        15 (23.4)        18 (22.8)        16 (21.6)        14 (19.4)        13 (28.9)        
                                                                                                                                           
  DRV/RTV               Total        1 (2.3)          4 (7.5)          4 (6.3)          9 (11.4)         26 (35.1)        32 (44.4)        7 (15.6)
  \<50                  1 (2.3)      3 (5.7)          3 (4.7)          7 (8.9)          16 (21.6)        20 (27.8)        6 (13.3)         
  ≥50                   --           1 (1.9)          1 (1.6)          2 (2.5)          10 (13.5)        12 (16.7)        1 (2.2)          
                                                                                                                                           
  DRV/COBI              Total        --               --               --               --               --               --               4 (8.9)
  \<50                  --           --               --               --               --               --               2 (4.4)          
  ≥50                   --           --               --               --               --               --               2 (4.4)          
  IDV                   Total        3 (6.8)          2 (3.8)          2 (3.1)          1 (1.3)          --               --               --
  \<50                  2 (4.5)      1 (1.9)          1 (1.6)          --               --               --               --               
  ≥50                   1 (2.3)      1 (1.9)          1 (1.6)          1 (1.3)          --               --               --               
                                                                                                                                           
  DRV                   Total        --               --               --               --               1 (1.4)          --               --
  \<50                  --           --               --               --               --               --               --               
  ≥50                   --           --               --               --               1 (1.4)          --               --               
                                                                                                                                           
  **INSTIs**                         **(n**=**1)**    **(n**=**10)**   **(n**=**20)**   **(n**=**26)**   **(n**=**51)**   **(n**=**65)**   **(n**=**112)**
                                                                                                                                           
  DTG                   Total        --               --               --               --               1 (2.0)          11 (16.9)        36 (32.1)
  \<50                  --           --               --               --               1 (2.0)          8 (12.3)         22 (19.6)        
  ≥50                   --           --               --               --               --               3 (4.6)          14 (12.5)        
                                                                                                                                           
  EVG/COBI              Total        --               --               --               --               20 (39.2)        30 (46.2)        64 (57.1)
  \<50                  --           --               --               --               12 (23.5)        18 (27.7)        34 (30.4)        
  ≥50                   --           --               --               --               8 (15.7)         12 (18.5)        30 (26.8)        
                                                                                                                                           
  RAL                   Total        1 (100.0)        10 (100.0)       20 (100.0)       26 (100.0)       30 (58.8)        24 (36.9)        12 (10.7)
  \<50                  1 (100.0)    2 (20.0)         7 (35.0)         9 (34.6)         11 (21.6)        8 (12.3)         7 (6.3)          
  ≥50                   --           8 (80.0)         13 (65.0)        17 (65.4)        19 (37.3)        16 (24.6)        5 (4.5)          

**Abbreviations:** 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; COBI, cobicistat; d4T, stavudine; ddI, didanosine; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; EVG, elvitegravir; FTC, emtricitabine; IDV, indinavir; INSTIs, integrase strand transfer inhibitors; LPV, lopinavir; NNRTIs, nonnucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NVP, nevirapine; PIs, protease inhibitors; RAL, raltegravir; RPV, rilpivirine; RTV, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.

###### 

Coadministered drug classes with antiretrovirals among the patients included in the study

  Class                                                    All patients, n (%) (n=183)   \<50 years, n (%) (n=104)   ≥50 years, n (%) (n=79)   *P*-value
  -------------------------------------------------------- ----------------------------- --------------------------- ------------------------- -----------
  Alimentary tract and metabolism                          105 (57.4)                    48 (46.2)                   57 (72.2)                 \<0.001
  Anti-infectives for systemic use                         77 (42.1)                     45 (43.3)                   32 (40.5)                 0.708
  Dermatologicals                                          49 (26.8)                     20 (19.2)                   29 (36.7)                 0.008
  Musculoskeletal system                                   47 (25.7)                     28 (26.9)                   19 (24.1)                 0.660
  Nervous system                                           47 (25.7)                     23 (22.1)                   24 (30.4)                 0.205
  Respiratory system                                       44 (24.0)                     23 (22.1)                   21 (26.6)                 0.484
  Cardiovascular system                                    43 (23.5)                     18 (17.3)                   25 (31.6)                 0.023
  Systemic hormonal preparations, excluding sex hormones   22 (12.0)                     13 (12.5)                   9 (11.4)                  0.819
  Blood and blood forming organs                           20 (10.9)                     7 (6.7)                     13 (16.5)                 0.037
  Genitourinary system and sex hormones                    18 (9.8)                      5 (4.8)                     13 (16.5)                 0.009
  Antineoplastic and immunomodulating agents               10 (5.5)                      7 (6.7)                     3 (3.8)                   0.518
  Sensory organs                                           7 (3.2)                       3 (2.9)                     4 (5.1)                   0.467
  Antiparasitic products, insecticides, and repellents     2 (1.1)                       1 (1.0)                     1 (1.3)                   0.845

###### 

Potential or contraindicated drug--drug interactions between antiretrovirals and other drugs coprescribed with antiretrovirals

  Antiretroviral drug             Comedication           Frequency, n (%) (n=194)   Strength of recommendation[a](#tfn4-tcrm-14-2229){ref-type="table-fn"}   Quality of evidence[b](#tfn5-tcrm-14-2229){ref-type="table-fn"}
  ------------------------------- ---------------------- -------------------------- ------------------------------------------------------------------------ -----------------------------------------------------------------
                                                                                                                                                             
  **NRTIs**                                                                                                                                                  
                                                                                                                                                             
  3TC                             Amphotericin           1 (0.5)                    Potential interaction                                                    Very low
  TDF                             Acyclovir              5 (2.6)                    Potential interaction                                                    Very low
  Celecoxib                       2 (1.0)                Potential interaction      Very low                                                                 
  Clarithromycin                  1 (0.5)                Potential interaction      Very low                                                                 
  Ganciclovir                     4 (2.1)                Potential interaction      Very low                                                                 
  Naproxen                        3 (1.5)                Potential interaction      Very low                                                                 
  Nimesulide                      6 (3.1)                Potential interaction      Very low                                                                 
  Pentamidine                     1 (0.5)                Potential interaction      Very low                                                                 
  Topiramate                      1 (0.5)                Potential interaction      Very low                                                                 
  Verapamil                       1 (0.5)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  ZDV                             Fluconazole            2 (1.0)                    Potential interaction                                                    Low
  Trimethoprim/sulfamethoxazole   1 (0.5)                Potential interaction      Low                                                                      
                                                                                                                                                             
  **NNRTIs**                                                                                                                                                 
                                                                                                                                                             
  EFV                             Amlodipine             1 (0.5)                    Potential interaction                                                    Very low
  Moxifloxacin                    1 (0.5)                Potential interaction      Very low                                                                 
  Nimesulide                      1 (0.5)                Potential interaction      Very low                                                                 
  Zolpidem                        1 (0.5)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  ETR                             Clarithromycin         1 (0.5)                    Potential interaction                                                    Moderate
  Fluconazole                     2 (1.0)                Potential interaction      Low                                                                      
  Glimepiride                     2 (1.0)                Potential interaction      Very low                                                                 
  Lercanidipine                   1 (0.5)                Potential interaction      Very low                                                                 
  Naproxen                        1 (0.5)                Potential interaction      Very low                                                                 
  Oxycodone                       1 (0.5)                Potential interaction      Very low                                                                 
  Rifampicin                      1 (0.5)                Do not coadminister        Moderate                                                                 
  Sildenafil                      1 (0.5)                Potential interaction      High                                                                     
  Tamsulosin                      1 (0.5)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  RPV                             Diltiazem              1 (0.5)                    Potential interaction                                                    Very low
  Famotidine                      2 (1.0)                Potential interaction      Low                                                                      
  Fluconazole                     1 (0.5)                Potential interaction      Very low                                                                 
  Itraconazole                    1 (0.5)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  **PIs**                                                                                                                                                    
                                                                                                                                                             
  ATV                             Atovaquone/proguanil   1 (0.5)                    Potential interaction                                                    Moderate
  Buspirone                       1 (0.5)                Potential interaction      Very low                                                                 
  Clarithromycin                  1 (0.5)                Potential interaction      Low                                                                      
  Escitalopram                    1 (0.5)                Potential interaction      Very low                                                                 
  Famotidine                      2 (1.0)                Potential interaction      Low                                                                      
  Lansoprazole                    1 (0.5)                Do not coadminister        Low                                                                      
  Nortriptyline                   2 (1.0)                Potential interaction      Very low                                                                 
  Prednisolone                    1 (0.5)                Potential interaction      Very low                                                                 
  Rifabutin                       1 (0.5)                Potential interaction      High                                                                     
  Tamsulosin                      1 (0.5)                Potential interaction      Very low                                                                 
  Zolpidem                        1 (0.5)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  ATV/COBI                        Atorvastatin           1 (0.5)                    Potential interaction                                                    Very low
                                                                                                                                                             
  ATV/RTV                         Atorvastatin           2 (1.0)                    Potential interaction                                                    Very low
  Clopidogrel                     1 (0.5)                Do not coadminister        Low                                                                      
  Methylprednisolone              1 (0.5)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  LPV/RTV                         Alfuzosin              1 (0.5)                    Do not coadminister                                                      Moderate
  Alprazolam                      1 (0.5)                Potential interaction      Very low                                                                 
  Amlodipine                      3 (1.5)                Potential interaction      Very low                                                                 
  Azithromycin                    1 (0.5)                Potential interaction      Very low                                                                 
  Atorvastatin                    8 (4.1)                Potential interaction      High                                                                     
                                  Clarithromycin         3 (1.5)                    Potential interaction                                                    Very low
  Clindamycin                     1 (0.5)                Potential interaction      Very low                                                                 
  Estradiol                       1 (0.5)                Potential interaction      Very low                                                                 
  Fentanyl                        2 (1.0)                Potential interaction      Very low                                                                 
  Gliclazide                      1 (0.5)                Potential interaction      Very low                                                                 
  Glimepiride                     4 (2.1)                Potential interaction      Very low                                                                 
  Hydroxyzine                     3 (1.5)                Potential interaction      Very low                                                                 
  Lacidipine                      1 (0.5)                Potential interaction      Very low                                                                 
  Methylprednisolone              2 (1.0)                Potential interaction      Very low                                                                 
  Mirtazapine                     2 (1.0)                Potential interaction      Very low                                                                 
  Nortriptyline                   2 (1.0)                Potential interaction      Very low                                                                 
  Nifedipine                      1 (0.5)                Potential interaction      Very low                                                                 
  Oxcarbazepine                   1 (0.5)                Potential interaction      Very low                                                                 
  Quetiapine                      1 (0.5)                Do not coadminister        Very low                                                                 
  Rifabutin                       1 (0.5)                Potential interaction      High                                                                     
  Rifampicin                      1 (0.5)                Do not coadminister        High                                                                     
  Risperidone                     1 (0.5)                Potential interaction      Very low                                                                 
  Sildenafil                      1 (0.5)                Potential interaction      High                                                                     
  Simvastatin                     1 (0.5)                Do not coadminister        Moderate                                                                 
  Tadalafil                       2 (1.0)                Potential interaction      High                                                                     
  Tamsulosin                      1 (0.5)                Potential interaction      Very low                                                                 
  Trazodone                       1 (0.5)                Potential interaction      Moderate                                                                 
  Valproate                       1 (0.5)                Potential interaction      Moderate                                                                 
  Voriconazole                    1 (0.5)                Potential interaction      Moderate                                                                 
  Zolpidem                        6 (3.1)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  DRV/RTV                         Atorvastatin           3 (1.5)                    Potential interaction                                                    High
  Atovaquone/proguanil            1 (0.5)                Potential interaction      Very low                                                                 
  Clarithromycin                  1 (0.5)                Potential interaction      Moderate                                                                 
  Clopidogrel                     1 (0.5)                Do not coadminister        Low                                                                      
  Colchicine                      1 (0.5)                Potential interaction      Very low                                                                 
  Glimepiride                     1 (0.5)                Potential interaction      Very low                                                                 
  Hydrocortisone                  1 (0.5)                Potential interaction      Very low                                                                 
  Hydroxyzine                     2 (1.0)                Potential interaction      Very low                                                                 
  Itraconazole                    1 (0.5)                Potential interaction      Very low                                                                 
  Methylprednisolone              1 (0.5)                Potential interaction      Very low                                                                 
  Nifedipine                      1 (0.5)                Potential interaction      Very low                                                                 
  Oxycodone                       1 (0.5)                Potential interaction      Very low                                                                 
  Prednisolone                    2 (1.0)                Potential interaction      Very low                                                                 
  Quetiapine                      1 (0.5)                Do not coadminister        Very low                                                                 
  Rifabutin                       1 (0.5)                Potential interaction      Low                                                                      
  Sildenafil                      1 (0.5)                Potential interaction      Very low                                                                 
  Valproate                       1 (0.5)                Potential interaction      Very low                                                                 
  Zolpidem                        3 (1.5)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  IDV                             Glimepiride            1 (0.5)                    Potential interaction                                                    Very low
                                                                                                                                                             
  **INSTIs**                                                                                                                                                 
                                                                                                                                                             
  DTG                             Magnesium              1 (0.5)                    Potential interaction                                                    Very low
  Metformin                       5 (2.6)                Potential interaction      Low                                                                      
                                                                                                                                                             
  EVG/COBI                        Alprazolam             1 (0.5)                    Potential interaction                                                    Very low
  Amlodipine                      2 (1.0)                Potential interaction      Very low                                                                 
  Atorvastatin                    1 (0.5)                Potential interaction      Very low                                                                 
  Clonazepam                      1 (0.5)                Potential interaction      Very low                                                                 
  Dexamethasone                   1 (0.5)                Potential interaction      Very low                                                                 
  Fentanyl                        1 (0.5)                Potential interaction      Very low                                                                 
  Glimepiride                     1 (0.5)                Potential interaction      Very low                                                                 
  Hydroxyzine                     1 (0.5)                Potential interaction      Very low                                                                 
  Iron supplement                 1 (0.5)                Potential interaction      Very low                                                                 
  Itraconazole                    1 (0.5)                Potential interaction      Very low                                                                 
  Magnesium                       1 (0.5)                Potential interaction      Very low                                                                 
  Metformin                       2 (1.0)                Potential interaction      Very low                                                                 
  Midazolam                       1 (0.5)                Potential interaction      Very low                                                                 
  Nifedipine                      1 (0.5)                Potential interaction      Very low                                                                 
  Phenytoin                       1 (0.5)                Do not coadminister        Very low                                                                 
  Quetiapine                      1 (0.5)                Do not coadminister        Very low                                                                 
  Rifabutin                       1 (0.5)                Potential interaction      Low                                                                      
  Rifampicin                      1 (0.5)                Do not coadminister        Moderate                                                                 
  Saxagliptin                     1 (0.5)                Potential interaction      Very low                                                                 
  Sildenafil                      1 (0.5)                Potential interaction      Very low                                                                 
  Tamsulosin                      1 (0.5)                Potential interaction      Very low                                                                 
  Trazodone                       1 (0.5)                Potential interaction      Very low                                                                 
  Valproate                       1 (0.5)                Potential interaction      Very low                                                                 
  Zolpidem                        5 (2.6)                Potential interaction      Very low                                                                 
                                                                                                                                                             
  RAL                             Calcium supplement     1 (0.5)                    Potential interaction                                                    Very low
  Iron supplement                 2 (1.0)                Potential interaction      Very low                                                                 
  Magnesium                       6 (3.1)                Potential interaction      Very low                                                                 
  Rifampicin                      2 (1.0)                Potential interaction      Moderate                                                                 

**Notes:**

Do not coadminister: these drugs should not be coadministered; Potential interaction: potential clinically significantly interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration.

Find more information on quality of evidence at the following website: <https://www.hiv-druginteractions.org/>.

**Abbreviations:** 3TC, lamivudine; ATV, atazanavir; COBI, cobicistat; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; ETR, etravirine; EVG, elvitegravir; IDV, indinavir; INSTIs, integrase strand transfer inhibitors; LPV, lopinavir; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; RAL, raltegravir; RPV, rilpivirine; RTV, ritonavir; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.

[^1]: These authors contributed equally to this work
